A Double-Negative Feedback Interaction between miR-21 and PPAR-α in Clear Renal Cell Carcinoma.
AP-1
NF-κB
PPAR-α
ccRCC
lipid
miR-21
renal cancer
transcriptional regulation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
04 Feb 2022
04 Feb 2022
Historique:
received:
22
12
2021
revised:
27
01
2022
accepted:
31
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Clear cell renal cell carcinoma (ccRCC) is the main histotype of kidney cancer, which is typically highly resistant to conventional therapies and known for abnormal lipid accumulation. In this context, we focused our attention on miR-21, an oncogenic miRNA overexpressed in ccRCC, and peroxysome proliferator-activated receptor-α (PPAR- α), one master regulator of lipid metabolism targeted by miR-21. First, in a cohort of 52 primary ccRCC samples, using RT-qPCR and immunohistochemistry, we showed that miR-21 overexpression was correlated with PPAR-α downregulation. Then, in ACHN and 786-O cells, using RT-qPCR, the luciferase reporter gene, chromatin immunoprecipitation, and Western blotting, we showed that PPAR-α overexpression (i) decreased miR-21 expression, AP-1 and NF-κB transcriptional activity, and the binding of AP-1 and NF-κB to the miR-21 promoter and (ii) increased PTEN and PDCD4 expressions. In contrast, using pre-miR-21 transfection, miR-21 overexpression decreased PPAR-α expression and transcriptional activity mediated by PPAR-α, whereas the anti-miR-21 (LNA-21) strategy increased PPAR-α expression, but also the expression of its targets involved in fatty acid oxidation. In this study, we showed a double-negative feedback interaction between miR-21 and PPAR-α. In ccRCC, miR-21 silencing could be therapeutically exploited to restore PPAR-α expression and consequently inhibit the oncogenic events mediated by the aberrant lipid metabolism of ccRCC.
Identifiants
pubmed: 35159062
pii: cancers14030795
doi: 10.3390/cancers14030795
pmc: PMC8834244
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Am J Physiol Renal Physiol. 2020 Aug 1;319(2):F202-F214
pubmed: 32628541
Commun Biol. 2020 Nov 13;3(1):677
pubmed: 33188287
Int J Mol Sci. 2021 Oct 27;22(21):
pubmed: 34769029
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
pubmed: 16461460
Cancers (Basel). 2021 Nov 28;13(23):
pubmed: 34885091
Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12449-54
pubmed: 16099833
Mol Biol Cell. 2007 Jun;18(6):2013-25
pubmed: 17392517
Transl Androl Urol. 2020 Dec;9(6):2751-2763
pubmed: 33457247
J Am Soc Nephrol. 2018 Apr;29(4):1223-1237
pubmed: 29440279
PLoS One. 2013;8(2):e58014
pubmed: 23469132
J Mol Biol. 2008 May 2;378(3):492-504
pubmed: 18384814
Biochem J. 2005 Feb 15;386(Pt 1):35-45
pubmed: 15461591
Future Med Chem. 2021 Nov;13(21):1885-1906
pubmed: 34590501
Brief Bioinform. 2015 Jan;16(1):45-58
pubmed: 24307685
Metabolism. 2017 Jun;71:33-45
pubmed: 28521876
Int J Oncol. 2013 Oct;43(4):995-1001
pubmed: 23913120
Oncotarget. 2014 Feb 15;5(3):754-63
pubmed: 24504508
Nat Commun. 2017 Nov 24;8(1):1769
pubmed: 29176561
Cancer Cell Int. 2021 Mar 17;21(1):175
pubmed: 33731131
Nat Rev Nephrol. 2017 Jul;13(7):410-419
pubmed: 28480903
Tumour Biol. 2017 Jul;39(7):1010428317707372
pubmed: 28714373
Trends Cancer. 2020 Jun;6(6):448-450
pubmed: 32459999
Pathol Res Pract. 2015 Jul;211(7):505-12
pubmed: 25908108
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
J Cancer. 2020 Jan 14;11(6):1478-1485
pubmed: 32047554
Int J Mol Sci. 2021 Dec 04;22(23):
pubmed: 34884928
Int J Mol Sci. 2021 Aug 20;22(16):
pubmed: 34445672
Cancers (Basel). 2021 Nov 22;13(22):
pubmed: 34831009
Int J Mol Sci. 2019 Apr 23;20(8):
pubmed: 31018516
Cancer Res. 2009 Jul 15;69(14):5707-15
pubmed: 19549898
Metabolites. 2020 Dec 13;10(12):
pubmed: 33322148
J Biol Chem. 1999 Nov 5;274(45):32048-54
pubmed: 10542237
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Trends Pharmacol Sci. 2014 Mar;35(3):119-26
pubmed: 24560301
Cancer Lett. 2014 May 1;346(2):225-36
pubmed: 24384091
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Pharm Res. 2011 Oct;28(10):2467-76
pubmed: 21562928
Metabolites. 2021 Sep 07;11(9):
pubmed: 34564424
Oncotarget. 2014 Feb 28;5(4):1004-13
pubmed: 24657971
Biosci Rep. 2011 Jun;31(3):185-97
pubmed: 20815812
Mol Ther Nucleic Acids. 2020 Jun 5;20:409-420
pubmed: 32244168
Cell Metab. 2013 Mar 5;17(3):466-466.e2
pubmed: 23473039
J Hepatol. 2015 Mar;62(3):720-33
pubmed: 25450203
J Pharmacol Sci. 2019 Sep;141(1):70-78
pubmed: 31611175
Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10355-60
pubmed: 21636785